News: Regeneron Pharmaceuticals Inc (REGN.OQ)
271.42USD
12:55pm EDT
$-6.87 (-2.47%)
$278.29
$277.64
$277.64
$271.36
68,696
220,530
$283.00
$131.50
Thu, May 30 2013
UK cost agency recommends Bayer, Regeneron eye drug
LONDON, May 31 - Britain's healthcare cost watchdog NICE is recommending a new eye drug from Bayer and Regeneron, after a price discount was offered for its use on the state health service.
Regeneron settles all pending litigation with Roche's Genentech
May 20 - Regeneron Pharmaceuticals Inc said it settled all pending litigation with Roche Holding AG's unit Genentech on the company's eye drug, Eylea, and cancer drug, Zaltrap.
FEATURE-Fast climbing biotech Regeneron still has room to grow
* Shares jump five-fold in two years, market value $26 bln
UPDATE 2-Regeneron raises Eylea sales view, shares hit all-time high
* Shares hit life-high of $270 (Adds comments from conference call, analyst comment)
Regeneron raises 2013 Eylea sales view, profit beats Street
- Regeneron Pharmaceuticals Inc's first-quarter results beat analysts' estimates for the seventh straight quarter as sales of its eye drug Eylea continued to gather pace, and the company raised its 2013 sales estimate for the drug.
Regeneron raises 2013 Eylea sales view, profit beats Street
May 3 - Regeneron Pharmaceuticals Inc's first-quarter results beat analysts' estimates for the seventh straight quarter as the sales of its eye drug Eylea continued to gather pace, and the company raised its 2013 sales estimate for the drug.
UPDATE 3-Allergan delays drug that would rival Regeneron's Eylea
May 1 - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.
BRIEF-Regeneron Pharma shares resume trading, up 16 percent
NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares resume trading, up 16 percent * Shares as shares of Allergan slide after co says vision drug approval
BRIEF-Regeneron Pharma shares halted, last up 14.3 pct
NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares halted, last up 14.3 percent
BRIEF-Regeneron Pharma shares up 2.8 pct after the bell
NEW YORK, April 24 - Regeneron Pharmaceuticals Inc : * Shares up 2.8 percent after the bell, to join S&P 500 next week
- Cramer's Lightning Round - Regeneron Is The Real Deal (7/31/13)
- Cramer Quick Take: What's Next for Biotech?
- Cramer's Mad Money - Facebook's Triumph (7/25/13)
- Ohr Phramaceuticals: Eye Drop Treatment For Wet AMD Could Sideline Eylea Momentum
- Sanofi, Amgen, Pfizer In Race For New Cholesterol Drug
- 4 Noteworthy Upgrades That You Should Question
Press Releases
- EYLEA® (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
- Regeneron Named Biotechnology Company of the Year
- Regeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
- EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
- ZALTRAP® (ziv-aflibercept) Receives CHMP Positive Opinion in the European Union for Previously Treated Metastatic Colorectal Cancer
- Regeneron Announces November 2012 Investor Conference Presentations
- Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
- Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
- Identifying Opportunity, Placing Risk - Consensus Reports on Biogen Idec Inc. and Regeneron Pharmaceuticals, Inc.
- Regeneron Reports Third Quarter 2012 Financial and Operating Results

